CE

CELLUMED CO., LTD.

Develops bone grafts, artificial joints, and enzymes for the biopharmaceutical sector.

049180 | KO

Overview

Corporate Details

ISIN(s):
KR7049180003
LEI:
Country:
South Korea
Address:
서울특별시 금천구 디지털로 130 402(가산동, 에이스테크노타워 9차), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CELLUMED CO., LTD. is a biotechnology company specializing in the development and manufacturing of medical devices and biologics. A pioneer in tissue banking, the company provides a range of bone graft materials, including allografts and xenografts, supported by advanced tissue processing technologies. Its product portfolio also includes musculoskeletal medical devices, such as artificial knee joints. Additionally, Cellumed supplies high-quality enzymes essential for the production of RNA-based medicines and vaccines, catering to the biopharmaceutical sector.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-19 00:00
Share Issue/Capital Change
기타주요경영사항 (제3자배정 유상증자 소액공모 철회의 건)
Korean 6.5 KB
2025-09-19 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 31.4 KB
2025-09-19 00:00
Share Issue/Capital Change
[기재정정]소액공모공시서류(지분증권)
Korean 1.9 MB
2025-09-19 00:00
Share Issue/Capital Change
소액공모실적보고서
Korean 26.0 KB
2025-08-26 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 109.8 KB
2025-08-25 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (채권압류 및 전부명령 항고 취하의 건)
Korean 8.2 KB
2025-08-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 72.5 KB
2025-08-18 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (집행판결 청구소송 합의의 건)
Korean 13.8 KB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 12.2 KB
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 1.9 MB
2025-07-28 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구) (특허권 압류명령)
Korean 12.3 KB
2025-07-25 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (채권압류 및 전부명령 판결에 대한 항고의 건)
Korean 10.0 KB
2025-07-11 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (주식압류명령의 판결에 대한 항고의 건)
Korean 9.3 KB
2025-06-13 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구) (채권압류 및 전부명령)
Korean 12.5 KB
2025-06-13 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구) (주식압류명령)
Korean 14.2 KB

Automate Your Workflow. Get a real-time feed of all CELLUMED CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CELLUMED CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CELLUMED CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
Trevi Therapeutics, Inc. Logo
Clinical-stage biopharma developing an oral therapy for chronic cough in IPF and RCC.
United States of America
TRVI
TRINITY BIOTECH PLC Logo
Develops and markets clinical diagnostic test kits and biosensors for labs and point-of-care.
United States of America
TRIB
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD
UCB Logo
UCB
Biopharma firm developing treatments for severe neurological and immunological diseases.
Belgium
UCB
Ultragenyx Pharmaceutical Inc. Logo
Develops and commercializes novel therapies for rare and ultra-rare genetic diseases.
United States of America
RARE
Develops biopharma therapies for endocrinology, ophthalmology, and dermatology needs.
Hong Kong
690
Unicycive Therapeutics, Inc. Logo
A clinical-stage biotech developing novel treatments for kidney diseases, led by oxylanthanum carbonate.
United States of America
UNCY

Talk to a Data Expert

Have a question? We'll get back to you promptly.